8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Apr 1, 2026·SEC
OrthoPediatrics Corp.(KIDS)Earnings, Financials & Key Ratios
KIDS•NASDAQ
$20.30
Price updated Jun 27, 2026
AboutOrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.Show more
- Revenue$236M+15.4%
- EBITDA-$8M+25.8%
- Net Income-$40M-4.8%
- EPS (Diluted)-1.69-3.0%
- Gross Margin73.05%+0.6%
- EBITDA Margin-3.28%+35.7%
- Operating Margin-12.27%+14.9%
- Net Margin-16.78%+9.2%
- ROE-11.31%-9.4%
KIDS Price & Volume
OrthoPediatrics Corp. (KIDS) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Challenges Pediatric Growth Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and capital constraints
"OrthoPediatrics maintains a specialized market position with robust 73.1% gross margins, yet the company faces significant headwinds as revenue growth decelerates to 13.3% and operating leverage remains elusive. The reliance on heavy capital expenditures for instrument placements, combined with a dwindling cash position of $12.2M, creates a precarious financial profile that necessitates urgent operational improvements. Investors should monitor the company's ability to convert its niche product portfolio into sustainable free cash flow before the current liquidity buffer is exhausted."
Verdict Logic
the company's cash position has plummeted to $12.2M as of 2026Q1, signaling a high risk of dilutive financing to sustain operations given the persistent net loss of $10.7M.
KIDS Growth Metrics
OrthoPediatrics Corp. (KIDS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years22.52%
5 Years27.16%
3 Years24.56%
TTM14.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM2.46%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM4%
Return on Capital
10 Years-10.18%
5 Years-6.82%
3 Years-6.74%
Last Year-6.43%
KIDS Recent Earnings
OrthoPediatrics Corp. (KIDS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.42-10.5%
$0.38
Rev
$59M+1.8%
$58M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.26+29.7%
$0.37
Rev
$62M+2.4%
$60M
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$0.24+7.7%
$0.26
Rev
$61M+3.3%
$59M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.11+35.3%
$0.17
Rev
$61M-0.5%
$61M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.42vs $0.38-10.5% | $59Mvs $58M+1.8% |
| Q1 2026 | Feb 26, 2026 | $0.26vs $0.37+29.7% | $62Mvs $60M+2.4% |
| Q4 2025 | Oct 28, 2025 | $0.24vs $0.26+7.7% | $61Mvs $59M+3.3% |
| Q3 2025 | Aug 5, 2025 | $0.11vs $0.17+35.3% | $61Mvs $61M-0.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for OrthoPediatrics Corp. (KIDS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $20.30 | $513.16M | -12.01 | 15.45% | -16.78% | -11.31% | — | |
| $9.30 | $1.41B | -9.69 | 24.95% | -21.07% | -443.09% | — | |
| $0.42 | $58.92M | 14.00 | 14.21% | 1.5% | 3.68% | — | |
| $86.25 | $11.63B | 22.00 | 16.65% | 18.92% | 13.04% | — | |
| $93.10 | $18.23B | 26.23 | 7.2% | 9.05% | 5.77% | — | |
| $332.31 | $127.39B | 39.56 | 11.16% | 13.21% | 15.1% | — |
Compare KIDS vs Peers
OrthoPediatrics Corp. (KIDS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KIDS SEC Filings & Documents
OrthoPediatrics Corp. (KIDS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when KIDS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KIDS Frequently Asked Questions
OrthoPediatrics Corp. (KIDS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is OrthoPediatrics Corp.'s revenue?
OrthoPediatrics Corp. (KIDS) reported $243.3M in revenue for fiscal year 2025. This represents a 927% increase from $23.7M in 2014.
How fast is OrthoPediatrics Corp. growing?
OrthoPediatrics Corp. (KIDS) grew revenue by 15.4% over the past year. This is strong growth.
Is KIDS profitable?
OrthoPediatrics Corp. (KIDS) reported a net loss of $39.7M for fiscal year 2025.
Dividend & Returns
What is KIDS's return on equity?
OrthoPediatrics Corp. (KIDS) has a return on equity (ROE) of -11.3%. Negative ROE indicates the company is unprofitable.
What is OrthoPediatrics Corp.'s free cash flow?
OrthoPediatrics Corp. (KIDS) had negative free cash flow of $12.6M in fiscal year 2025, likely due to heavy capital investments.